All systems operational
Q3 2023

Current Practice of Oral Care for Hematopoietic Stem Cell Transplant Patients: A Survey of the Eastern Mediterranean Blood and Marrow Transplantation Group

Hani Mawardi · Nathaniel Treister · Osama Felemban · Waleed Alamoudi · Ghada Algohary · Abdulrahman Alsultan · Nawal Alshehri · Illias Tazi · Marwan Shaheen · Mohamed Alsharani · Salem Alshemmari · Mutlu Arat · Mohamed Amine Bekadja · Murtadha Al-Khabori · Samar Okaily · Natasha Ali · Husam Abujazar · Wasil Jastaniah · Amir Ali Hamidieh · Sharukh Hashmi · Mahmoud Aljurf
10.1016/j.hemonc.2021.01.006 393 Views 5 Citations
5
Citations
393
Views
Abstract


Introduction:
The oral cavity is one of the most common sites impacted by hematopoietic stem cell transplantation (HSCT) with acute complications including mucositis, bleeding, salivary gland dysfunction, infection, and taste alteration. These complications may result in significant morbidity and can negatively impact outcomes such as length of stay and overall costs. As such, oral care during HSCT for prevention and management of oral toxicities is a standard component of transplant protocols at all centers. The objective of this study was to evaluate the current oral care practices for patients during HSCT at different transplant centers within the Eastern Mediterranean region.


Material and methods:
An internet-based survey was directed to 30 transplant centers in the Eastern Mediterranean region. The survey included five sections asking questions related to (1) transplant center demographics; (2) current oral care protocol used at the center and type of collaboration (if any) with a dental service; (3) use of standardized oral assessment tools and grading systems for mucositis; (4) consultations for management of oral complications; and (5) oral health needs at each center. Data are presented as averages and percentages.


Results:
A total of 16 responses from 11 countries were collected and analyzed, indicating a response rate of 53%. Eight centers reported that a dentist was part of the HSCT team, with four reporting oral medicine specialists specifically being part of the team. Almost all centers (15/16; 93%) had an affiliated dental service to facilitate pre-HSCT dental clearance with an established dental clearance protocol at 14 centers (87%). Dental extraction was associated with the highest concern for bleeding and the need for platelet transfusion. With respect to infection risk, antibiotic prophylaxis was considered in the setting of low neutrophil counts with restorative dentistry and extraction. All centers provide daily reinforcement of oral hygiene regimen. The most frequently used mouth oral rinses included sodium bicarbonate (68%) and chlorhexidine gluconate (62%), in addition to ice chips for dry mouth (62%). The most frequently used mucositis assessment tools were the World Health Organization scale (7/16; 43%) and visual analogue scale for pain (6/16; 37%). Mucositis pain was managed with lidocaine solution (68.8%), magic mouth wash (68.8%) and/or systemic pain medications (75%).


Conclusions:
Scope and implementation of oral care protocols prior to and during HSCT varied between transplant centers. The lack of a universal protocol may contribute to gaps in oral healthcare needs and management for this group of patients. Further dissemination of and education around available oral care guidelines is warranted.
Clinical relevance.
Considering oral care during HSCT a standard component of transplant protocols, the current study highlights the common oral care practices for patients at centers within the Eastern Mediterranean region.

Cite this Article (APA)
Hani, M., Nathaniel, T., Osama, F., Waleed, A., Ghada, A., Abdulrahman, A., Nawal, A., Illias, T., Marwan, S., Mohamed, A., Salem, A., Mutlu, A., Mohamed, A. B., Murtadha, A., Samar, O., Natasha, A., Husam, A., Wasil, J., Amir, A. H., Sharukh, H., Mahmoud, A. (2023). Current Practice of Oral Care for Hematopoietic Stem Cell Transplant Patients: A Survey of the Eastern Mediterranean Blood and Marrow Transplantation Group. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2021.01.006
Related Papers
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Ghada M. ElGohary; Shahrukh Hashmi; Jan Styczynski; Mohamed A. Kharfan-Dabaja; R · 2022
80
cites
396
Molecular mediators of breast cancer metastasis
Ragini Yeeravalli; Amitava Das · 2021
39
cites
385
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia
Nosha Farhadfar; Ying Li; William S. May; Carolyn Brooke Adams · 2021
38
cites
389
Acute upper limb ischemia in a patient with COVID-19
Parminder Kaur; Firas Qaqa; Amr Ramahi; Yezin Shamoon; Monisha Singhal; Fayez Sh · 2021
35
cites
386
Access
View Full Text via DOI
Published in
ISSN 1658-3876
Quartile Q3
AMS Score 72
Field Medicine & Health Sciences
Publisher Elsevier / King Faisal Specialist H
Country 🇸🇦 Saudi Arabia
View Journal Profile →
Authors
Publication Details
Year 2023
Language English
Added 28 Jul 2026